Comparison of Effects of Propofol Combined with Different Doses of Esketamine for ECT in the Treatment of Depression: A Randomized Controlled Trial Protocol

References

• Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. doi:10.1016/S0140-6736(18)31948-2
   PubMed Web of Science ®Google Scholar
• The global burden of disease: 2004 update. Available from: https://www.who.int/publications-detail-redirect/9789241563710. Accessed February 5, 2024.
   Google Scholar
• Subramanian S, Lopez R, Zorumski CF, Cristancho P. Electroconvulsive therapy in treatment resistant depression. J Neurol Sci. 2022;434:120095. doi:10.1016/j.jns.2021.120095
   PubMed Web of Science ®Google Scholar
• Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. doi:10.2147/NDT.S198774
   PubMed Web of Science ®Google Scholar
• Hsieh MH. Chapter 4 - Electroconvulsive therapy for treatment-resistant depression. In: Li CT, Cheng CM, editors. Progress in Brain Research. Vol 281. Treatment-Resistant Depression Part B. Elsevier; 2023:69–90. doi:10.1016/bs.pbr.2023.01.004
   Google Scholar
• Espinoza RT, Kellner CH. Electroconvulsive Therapy. N Engl J Med. 2022;386(7):667–672. doi:10.1056/NEJMra2034954
   PubMed Web of Science ®Google Scholar
• Brown SK, Nowlin RB, Sartorelli R, Smith J, Johnson K. Patient experience of electroconvulsive therapy: a retrospective review of clinical outcomes and satisfaction. J ECT. 2018;34(4):240–246. doi:10.1097/YCT.0000000000000492
   PubMed Web of Science ®Google Scholar
• Castaneda-Ramirez S, Becker TD, Bruges-Boude A, Kellner C, Rice TR. Systematic review: electroconvulsive therapy for treatment-resistant mood disorders in children and adolescents. Eur Child Adolesc Psychiatry. 2023;32(9):1529–1560. doi:10.1007/s00787-022-01942-7
   PubMed Web of Science ®Google Scholar
• Zhong X, He H, Zhang C, et al. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. J Affect Disord. 2016;201:124–130. doi:10.1016/j.jad.2016.05.011
   PubMed Web of Science ®Google Scholar
• Lima TDM, Visacri MB, Aguiar PM. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. Eur J Clin Pharmacol. 2022;78(3):311–338. doi:10.1007/s00228-021-03216-8
   PubMed Web of Science ®Google Scholar
• Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021;35(2):109–123. doi:10.1177/0269881120959644
   PubMed Web of Science ®Google Scholar
• Yuan R, Wen J, Xing Q, et al. Efficacy of pretreatment with remimazolam on prevention of propofol-induced injection pain in patients undergoing gastroscopy. Sci Rep. 2023;13(1):19683. doi:10.1038/s41598-023-47151-3
   PubMed Web of Science ®Google Scholar
• Sneyd JR, Absalom AR, Barends CRM, Jones JB. Hypotension during propofol sedation for colonoscopy: a retrospective exploratory analysis and meta-analysis. Br J Anaesth. 2022;128(4):610–622. doi:10.1016/j.bja.2021.10.044
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–534. doi:10.1016/j.jad.2019.11.086
   PubMed Web of Science ®Google Scholar
• Kocamer Şahin Ş, Demir B, Elboğa G, Altındağ A, Elmalı E. The effects of maintenance electroconvulsive therapy on hospitalization rates. J Nerv Ment Dis. 2021;209(3):155–158. doi:10.1097/NMD.0000000000001278
   PubMed Web of Science ®Google Scholar
• Gamble JJ, Bi H, Bowen R, et al. Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. Can J Anaesth. 2018;65(6):636–646. doi:10.1007/s12630-018-1088-0
   PubMed Web of Science ®Google Scholar
• Jauhar S, Morrison P. Esketamine for treatment resistant depression. BMJ. 2019;366:l5572. doi:10.1136/bmj.l5572
   PubMedGoogle Scholar
• Lin HT, Liu SK, Hsieh MH, et al. Impacts of electroconvulsive therapy on 1-year outcomes in patients with schizophrenia: a controlled, population-based mirror-image study. Schizophr Bull. 2018;44(4):798–806. doi:10.1093/schbul/sbx136
   PubMed Web of Science ®Google Scholar
• Kaster TS, Vigod SN, Gomes T, Sutradhar R, Wijeysundera DN, Blumberger DM. Risk of serious medical events in patients with depression treated with electroconvulsive therapy: a propensity score-matched, retrospective cohort study. Lancet Psychiatry. 2021;8(8):686–695. doi:10.1016/S2215-0366(21)00168-1
   PubMed Web of Science ®Google Scholar
• Rhee TG, Sint K, Olfson M, Gerhard T, Busch HS, Wilkinson ST. Association of ECT with risks of all-cause mortality and suicide in older medicare patients. Am J Psychiatry. 2021;178(12):1089–1097. doi:10.1176/appi.ajp.2021.21040351
   PubMed Web of Science ®Google Scholar
• Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019;364:l1079. doi:10.1136/bmj.l1079
   PubMedGoogle Scholar
• Tor PC, Tan XW, Martin D, Loo C. Comparative outcomes in electroconvulsive therapy (ECT): a naturalistic comparison between outcomes in psychosis, mania, depression, psychotic depression and catatonia. Eur Neuropsychopharmacol. 2021;51:43–54. doi:10.1016/j.euroneuro.2021.04.023
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lan X, Wang C, et al. Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2023. doi:10.1016/j.jaac.2023.05.031
   Google Scholar
• Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31. doi:10.1093/ijnp/pyaa068
   PubMed Web of Science ®Google Scholar
• Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. doi:10.4088/JCP.19m13191
   PubMed Web of Science ®Google Scholar
• Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555. doi:10.1016/j.jad.2020.09.071
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. doi:10.1176/appi.ajp.2020.20081251
   PubMed Web of Science ®Google Scholar
• Reif A, Bitter I, Buyze J, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389(14):1298–1309. doi:10.1056/NEJMoa2304145
   PubMed Web of Science ®Google Scholar
• Singh B, Kung S, Pazdernik V, et al. Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study. J Clin Psychiatry. 2023;84(2):22m14548. doi:10.4088/JCP.22m14548
   PubMed Web of Science ®Google Scholar
• Zaki N, Chen LN, Lane R, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023;48(8):1225–1233. doi:10.1038/s41386-023-01577-5
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, Chan PY, Yatham LN, Lam RW. Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. Br J Psychiatry. 2017;210(6):403–407. doi:10.1192/bjp.bp.116.195826
   PubMed Web of Science ®Google Scholar
• Ren L, Yu J, Zeng J, et al. Comparative efficacy and tolerability of different anesthetics in electroconvulsive therapy for major depressive disorder: a systematic review and network meta-analysis. J Psychiatr Res. 2024;171:116–125. doi:10.1016/j.jpsychires.2024.01.031
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affective Disorders. 2013;150(2):384–388. doi:10.1016/j.jad.2013.04.028
   PubMed Web of Science ®Google Scholar
• Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019;l1476. doi:10.1136/bmj.l1476
   PubMedGoogle Scholar
• Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. AJP. 2011;168(12):1266–1277. doi:10.1176/appi.ajp.2011.10111704
   Google Scholar
• McIntyre RS, Lipsitz O, Rodrigues NB, et al. An App-based digit symbol substitution test for assessment of cognitive deficits in adults with major depressive disorder: evaluation study. JMIR Ment Health. 2022;9(10):e33871. doi:10.2196/33871
   PubMed Web of Science ®Google Scholar
• Xu LL, Wang C, Deng CM, et al. Efficacy and safety of esketamine for supplemental analgesia during elective cesarean delivery: a randomized clinical trial. JAMA Network Open. 2023;6(4):e239321. doi:10.1001/jamanetworkopen.2023.9321
   PubMed Web of Science ®Google Scholar